H19 and non-small cell lung carcinoma: Its role in NSCLC targeted therapy resistance has been evaluated, which indicates that H19 can act as a facilitator of resistance to gefitinib, a representative first-generation tyrosine kinase inhibitor, by hnRNPA2B1-mediated incorporation in exosomes 111.